GTTX.CN
Price:
$0.12
Market Cap:
$3.38M
GeneTether Therapeutics Inc., a genetic medicines company, focuses on developing gene editing therapies to enhance the efficiency of genome editing technologies. It is developing gene therapies for the treatment of patients with rare and monogenic kidney and skin diseases. The company was founded in 2018 and is based in Kelowna, Canada.
Industry
Biotechnology
IPO Date
2022-03-30
Stock Exchange
CNQ
Ticker
GTTX.CN
According to GeneTether Therapeutics Inc.’s latest financial reports and current stock price. The company's current ROE is -22.88%. This represents a change of 57.54% compared to the average of -14.52% of the last 4 quarters.
The mean historical ROE of GeneTether Therapeutics Inc. over the last ten years is -8.02%. The current -22.88% ROE has changed 185.33% with respect to the historical average. Over the past ten years (40 quarters), GTTX.CN's ROE was at its highest in in the December 2022 quarter at 123.70%. The ROE was at its lowest in in the December 2021 quarter at -356.80%.
Average
-8.02%
Median
-50.16%
Minimum
-1041.75%
Maximum
1.05%
Discovering the peaks and valleys of GeneTether Therapeutics Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual ROE = 1.05%
Minimum Annual Increase = -1195.34%
Minimum Annual ROE = -1041.75%
| Year | ROE | Change |
|---|---|---|
| 2023 | -50.16% | -45.64% |
| 2022 | -92.27% | -91.14% |
| 2021 | -1041.75% | -1195.34% |
| 2020 | 95.11% | -90.93% |
The current ROE of GeneTether Therapeutics Inc. (GTTX.CN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-394.73%
5-year avg
-8.02%
10-year avg
-8.02%
GeneTether Therapeutics Inc.’s ROE is greater than Clearmind Medicine Inc. (-164.77%), greater than Awakn Life Sciences Corp. (-429.34%), greater than Asep Medical Holdings Inc (-17.04%), less than Tryp Therapeutics Inc. (402.50%), less than Bhang Inc. (510.77%), greater than Heritage Cannabis Holdings Corp. (-66.10%), less than 4Front Ventures Corp. (24.18%), less than MYND Life Sciences Inc. (35.68%), less than StageZero Life Sciences Ltd. (9.59%), greater than The BC Bud Corporation (-158.24%),
| Company | ROE | Market cap |
|---|---|---|
| -164.77% | $5.07M | |
| -429.34% | $3.86M | |
| -17.04% | $5.56M | |
| 402.50% | $5.79M | |
| 510.77% | $4.70M | |
| -66.10% | $4.72M | |
| 24.18% | $4.58M | |
| 35.68% | $3.35M | |
| 9.59% | $4.94M | |
| -158.24% | $5.02M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like GeneTether Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like GeneTether Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is GeneTether Therapeutics Inc.'s ROE?
How is the ROE calculated for GeneTether Therapeutics Inc. (GTTX.CN)?
What is the highest ROE for GeneTether Therapeutics Inc. (GTTX.CN)?
What is the 3-year average ROE for GeneTether Therapeutics Inc. (GTTX.CN)?
What is the 5-year average ROE for GeneTether Therapeutics Inc. (GTTX.CN)?
How does the current ROE for GeneTether Therapeutics Inc. (GTTX.CN) compare to its historical average?